down arrow

Adial Pharmaceuticals, Inc.

  • Market Cap: N/A
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: US00688A2050
USD
0.33
0.01 (4.25%)

Dec 04

NAS

 Click here to see other stocks
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryPrice Point
High/Low

1Day

0.300.33

52 Week

0.221.30
Valuation
Technical
Day's Volume

CASH

364.71 k

Shareholding (Mar 2025)

FII

0.01%

Held by 3 FIIs

DII

98.7%

Held by 1 DIIs

Promoter

0.00%

How big is Adial Pharmaceuticals, Inc.?

22-Jun-2025

As of Jun 18, Adial Pharmaceuticals, Inc. has a market capitalization of 2.51 million, with net sales of 0.00 million and a net profit of -8.95 million over the last four quarters. The company's shareholder's funds are 4.07 million, and total assets are 5.08 million.

Market Cap: As of Jun 18, Adial Pharmaceuticals, Inc. has a market capitalization of 2.51 million, classifying it as a Micro Cap company.<BR><BR>Recent Quarterly Performance: For the latest four quarters, Adial Pharmaceuticals, Inc. reported net sales of 0.00 million and a net profit of -8.95 million.<BR><BR>Balance Sheet Snapshot: As of Dec 24, the company's shareholder's funds amounted to 4.07 million, while total assets were reported at 5.08 million.

Read More

What does Adial Pharmaceuticals, Inc. do?

22-Jun-2025

Adial Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on developing treatments for addictions and related disorders, with a market cap of $2.51 million and a recent net profit of -$2 million. The company operates in the Pharmaceuticals & Biotechnology industry and is classified as a micro-cap entity.

Overview:<BR>Adial Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company engaged in the development of medications for the treatment of addictions and related disorders, operating within the Pharmaceuticals & Biotechnology industry and classified as a micro-cap company.<BR><BR>Financial Snapshot:<BR>Most recent Net Profit: -2 Million (Quarterly Results - Mar 2025)<BR>Market cap: USD 2.51 Million (Micro Cap)<BR><BR>Key Metrics:<BR>P/E: NA (Loss Making)<BR>Industry P/E: NA<BR>Dividend Yield: 0.00%<BR>Debt Equity: -1.11<BR>Return on Equity: -420.83%<BR>Price to Book: 1.18<BR><BR>Contact Details:<BR>Address: 1180 SEMINOLE TRAIL, SUITE 495, CHARLOTTESVILLE VA: 22901<BR>Tel: ['1 434 4229800', '1 212 6711021']<BR>Fax: 1 302 6555049<BR>Website: https://www.adialpharma.com/

Read More

Who are in the management team of Adial Pharmaceuticals, Inc.?

22-Jun-2025

As of March 2022, the management team of Adial Pharmaceuticals, Inc. includes President and CEO William Stilley, Vice Chairman Kevin Schuyler, and Independent Directors J. Kermit Anderson, Robertson Gilliland, Tony Goodman, and James Newman. They are responsible for the company's strategic direction and operations.

As of March 2022, the management team of Adial Pharmaceuticals, Inc. includes the following individuals:<BR><BR>- Mr. William Stilley, who serves as the President, Chief Executive Officer, and Director.<BR>- Mr. Kevin Schuyler, who holds the position of Vice Chairman and Lead Independent Director.<BR>- Mr. J. Kermit Anderson, who is an Independent Director.<BR>- Mr. Robertson Gilliland, who is also an Independent Director.<BR>- Mr. Tony Goodman, serving as an Independent Director.<BR>- Mr. James Newman, who is an Independent Director.<BR><BR>This team is responsible for guiding the company's strategic direction and operations.

Read More

Is Adial Pharmaceuticals, Inc. technically bullish or bearish?

20-Sep-2025

As of July 1, 2025, Adial Pharmaceuticals, Inc. is in a mildly bearish trend with mixed technical indicators, significantly underperforming the S&P 500 with a year-to-date decline of 65.20%.

As of 1 July 2025, the technical trend for Adial Pharmaceuticals, Inc. has changed from bearish to mildly bearish. The current stance is mildly bearish, with key indicators showing mixed signals. The MACD is mildly bullish on both weekly and monthly time frames, while the Bollinger Bands indicate a mildly bearish trend weekly and bearish monthly. Moving averages are bearish on a daily basis. The KST and OBV are mildly bullish and bullish respectively on the monthly time frame, but the RSI shows no signal. <BR><BR>In terms of performance, the stock has significantly underperformed compared to the S&P 500 across all multi-period returns, with a year-to-date decline of 65.20% versus the S&P 500's gain of 12.22%.

Read More
iScoreScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.

Dashboard
Icon
Unrated Stock - No Analysis Available
stock-summaryMojo Parameters
Mojo Parameters
Stock DNA
stock-summary
Industry

Pharmaceuticals & Biotechnology

stock-summary
Market cap

USD 8 Million ()

stock-summary
P/E

NA (Loss Making)

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

0.00%

stock-summary
Debt Equity

-1.06

stock-summary
Return on Equity

-151.14%

stock-summary
Price to Book

1.36

Revenue and Profits:
Net Sales:
(Quarterly Results - Jun 2025)
Net Profit:
-2 Million
stock-summaryTotal Returns
Total Returns (Price + Dividend) stock-summary
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
-12.78%
0%
-12.78%
6 Months
-50.46%
0%
-50.46%
1 Year
-70.61%
0%
-70.61%
2 Years
-82.92%
0%
-82.92%
3 Years
25.46%
0%
25.46%
4 Years
-99.51%
0%
-99.51%
5 Years
-99.34%
0%
-99.34%

Adial Pharmaceuticals, Inc. for the last several years.

Risk Adjusted Returns v/s stock-summary
stock-summaryNews & Corporate Actions
News

Is Adial Pharmaceuticals, Inc. technically bullish or bearish?

As of 1 July 2025, the technical trend for Adial Pharmaceuticals, Inc. has changed from bearish to mildly bearish. The current stance is mildly bearish, with key indicators showing mixed signals. The MACD is mildly bullish on both weekly and monthly time frames, while the Bollinger Bands indicate a mildly bearish trend weekly and bearish monthly. Moving averages are bearish on a daily basis. The KST and OBV are mildly bullish and bullish respectively on the monthly time frame, but the RSI shows no signal. In terms of performance, the stock has significantly underperformed compared to the S&P 500 across all multi-period returns, with a year-to-date decline of 65.20% versus the S&P 500's gain of 12.22%....

Read More
Announcements stock-summary
Icon
No announcement available
Corporate Actions stock-summary
Icon
No corporate action available
stock-summaryKey Factors
Quality key factors stock-summary
Factor
Value
Sales Growth (5y)
0
EBIT Growth (5y)
-0.87%
EBIT to Interest (avg)
-11.67
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-1.11
Sales to Capital Employed (avg)
0
Tax Ratio
0
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
9.53%
ROCE (avg)
0
ROE (avg)
0
Valuation key factors
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
2.12
EV to EBIT
-0.25
EV to EBITDA
-0.25
EV to Capital Employed
-2.15
EV to Sales
NA
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
Negative Capital Employed
ROE (Latest)
-420.83%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Mildly Bullish
Mildly Bullish
RSI
Bearish
No Signal
Bollinger Bands
Mildly Bearish
Bearish
Moving Averages
Bearish (Daily)
KST
Mildly Bullish
Bearish
Dow Theory
No Trend
Mildly Bearish
OBV
Mildly Bullish
No Trend
stock-summary Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
stock-summaryShareholding
Shareholding Snapshot : Mar 2025stock-summary
Shareholding Compare (%holding) stock-summary
Majority shareholders

Domestic Funds

Domestic Funds

Held in 3 Schemes (1.29%)

Foreign Institutions

Held by 3 Foreign Institutions (0.01%)

Strategic Entities with highest holding

Highest Public shareholder

stock-summaryFinancial
[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Jun'25 - YoY",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in quarter ended Jun 2025 is 0.00% vs 0.00% in Jun 2024",
        "dir": 0
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in quarter ended Jun 2025 is 20.00% vs -66.67% in Jun 2024",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Jun'25",
        "Jun'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-1.90",
          "val2": "-2.30",
          "chgp": "17.39%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-2.00",
          "val2": "-2.50",
          "chgp": "20.00%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "0.00%",
          "chgp": "NA",
          "chgp_class": "neutral"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'24",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2024 is 0.00% vs 0.00% in Dec 2023",
        "dir": 0
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2024 is -88.57% vs 35.19% in Dec 2023",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Dec'24",
        "Dec'23",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-8.30",
          "val2": "-6.90",
          "chgp": "-20.29%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-13.20",
          "val2": "-7.00",
          "chgp": "-88.57%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "0.00%",
          "chgp": "NA",
          "chgp_class": "neutral"
        }
      ]
    }
  }
]
Quarterly Results Snapshot (Consolidated) - Jun'25 - YoYstock-summary
Jun'25
Jun'24
Change(%)
Net Sales
0.00
0.00
Operating Profit (PBDIT) excl Other Income
-1.90
-2.30
17.39%
Interest
0.00
0.00
Exceptional Items
0.00
0.00
Consolidate Net Profit
-2.00
-2.50
20.00%
Operating Profit Margin (Excl OI)
0.00%
0.00%
NA
USD in Million.
stock-summary Compare with Peers
Net Sales

YoY Growth in quarter ended Jun 2025 is 0.00% vs 0.00% in Jun 2024

Direction Arrows
Consolidated Net Profit

YoY Growth in quarter ended Jun 2025 is 20.00% vs -66.67% in Jun 2024

All Quarterly Resultsstock-summary
Annual Results Snapshot (Consolidated) - Dec'24stock-summary
Dec'24
Dec'23
Change(%)
Net Sales
0.00
0.00
Operating Profit (PBDIT) excl Other Income
-8.30
-6.90
-20.29%
Interest
0.00
0.00
Exceptional Items
0.00
0.00
Consolidate Net Profit
-13.20
-7.00
-88.57%
Operating Profit Margin (Excl OI)
0.00%
0.00%
NA
USD in Million.
stock-summary Compare with Peers
Net Sales

YoY Growth in year ended Dec 2024 is 0.00% vs 0.00% in Dec 2023

Direction Arrows
Consolidated Net Profit

YoY Growth in year ended Dec 2024 is -88.57% vs 35.19% in Dec 2023

All Annual Resultsstock-summary
stock-summaryCompany CV
About Adial Pharmaceuticals, Inc. stock-summary
stock-summary
Adial Pharmaceuticals, Inc.
Pharmaceuticals & Biotechnology
Adial Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in the development of medications for the treatment of addictions and related disorders. Its lead investigational drug product is AD04. AD04 is being developed for the treatment of alcohol use disorder. The active ingredient in AD04 is ondansetron, a serotonin-3 antagonist. AD04 is being designed to be used for the treatment of other addictive disorders, such as opioid use disorder, obesity, smoking, and other drug addictions.
Company Coordinates stock-summary
Company Details
1180 SEMINOLE TRAIL, SUITE 495 , CHARLOTTESVILLE VA : 22901
stock-summary
Tel: 1 434 42298001 212 6711021
stock-summary
https://www.adialpharma.com/
stock-summary
Registrar Details
Stock List
ABCDEFGHIJKLMNOPQRSTUVWXYZOther
Footer Logo
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
Market
Webinars
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."